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ABSTRACT
Ceftazidime and cefotaxime are b-lactam antibiotics with dose-related afﬁnities for penicillin-binding
protein (PBP)-3 and PBP-1. At low concentrations, these antibiotics inhibit PBP-3, leading to ﬁlament
formation. Filaments are long strands of non-dividing bacteria that contain enhanced quantities of
endotoxin molecules. Higher concentrations of ceftazidime or cefotaxime cause inhibition of PBP-1,
resulting in rapid bacterial lysis, which is associated with low endotoxin release. In the present study, 37
isolates of Escherichia coli, Klebsiella spp., Pseudomonas aeruginosa and Acinetobacter spp.were studied over
a 4-h incubation period in the presence of eight concentrations of ceftazidime or cefotaxime. As
resistance of Gram-negative bacteria is an emerging problem in clinical practice, 14 isolates of E. coli and
Klebsiella pneumoniae that produced extended-spectrum b-lactamases (ESBLs) were also investigated.
Morphological changes after exposure to the b-lactam antibiotics revealed recognisable patterns in
various bacterial families, genera and isolates. In general, all isolates of Enterobacteriaceae produced
ﬁlaments within a relatively small concentration range, with similar patterns for E. coli and
K. pneumoniae. Pseudomonas and Acinetobacter spp. produced ﬁlaments in the presence of clinically-
relevant concentrations of both antibiotics as high as 50 mg ⁄L. In all genera, ﬁlament-producing capacity
was clearly related to the MIC. Ceftazidime induced ﬁlament production in more isolates and over
wider concentration ranges than did cefotaxime. Interestingly, ESBL-producing isolates were not
protected against ﬁlament induction. The induction of ﬁlament production may lead to additional risks
during empirical treatment of severe infections.
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INTRODUCTION
b-Lactam antibiotics act by inhibiting the penicil-
lin-binding-proteins (PBPs) anchored in the cyto-
plasmic membrane of Gram-negative bacteria [1].
Each PBP has a speciﬁc role in bacterial prolifer-
ation and maintenance of morphology. Blocking
of PBP-1 leads to rapid bacterial lysis, with rapid
release of relatively small amounts of endotoxin
[2]. Binding of b-lactam agents to PBP-3 results in
the formation of ﬁlaments, caused by the inability
of bacteria to septate after doubling of their cell
mass. Filaments are long strands of non-dividing
bacteria that contain enhanced quantities of endo-
toxin [2,3]. The mechanism by which the endo-
toxin content is enhanced is still unclear [4,5].
Endotoxin, or lipopolysaccharide, is known to be
a key mediator in Gram-negative bacterial infec-
tions [6–10], and the high endotoxin content of
ﬁlaments means that there is a risk of delayed, but
higher, release of endotoxin during ongoing
antibiotic treatment of infections [10–16]. Each
b-lactam agent has a speciﬁc binding afﬁnity for
different PBPs. Ceftazidime and cefotaxime, which
are oxyimino-containing cephalosporins, both
bind to PBP-3 at relatively low concentrations,
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and to PBP-1 at higher concentrations [2,17,18].
Reports concerning the concentrations at which
speciﬁc PBP-binding occurs are scarce [19].
Previous studies have revealed that ﬁlament-
inducing concentrations of ceftazidime vary, from
concentrations around the MIC for Escherichia coli
to concentrations >50 · MIC for Pseudomonas
aeruginosa [2,20].
Resistance to b-lactam antibiotics is a major
problem in clinical medicine. This problem is
typically caused by the acquisition of plasmids
carrying b-lactamase-encoding genes, including
those that encode extended-spectrum b-lactamas-
es (ESBLs). ESBL-producing Klebsiella pneumoniae
and E. coli strains are now relatively common in
healthcare settings throughout the world [21–26].
ESBLs are capable of efﬁciently hydrolysing
penicillins, narrow-spectrum cephalosporins,
many extended-spectrum cephalosporins, the
oxyimino cephalosporins and the monobactams
[27,28]. In addition to non-susceptibility, ﬁla-
ment induction may add the risk of accumula-
tion of large amounts of bacterial
lipopolysaccharide during initial empirical anti-
biotic therapy, when culture and MIC data are
not yet available.
The aim of the present study was to deter-
mine the concentrations of ceftazidime and
cefotaxime at which PBP-inhibitory effects
change, and to relate this to CFU counts and
MICs. The study also investigated whether these
antibiotics are capable of inducing ﬁlament
production in ESBL-producing isolates of En-
terobacteriaceae. It was hypothesised that ﬁla-
ment induction may be absent, or occur only at
higher antibiotic concentrations, in such isolates
following total or partial inactivation of antibi-
otics before binding to PPB-3.
MATERIALS AND METHODS
Bacteria
In total, 37 isolates of Gram-negative bacteria, collected mainly
during routine daily practice in the microbiological laboratory
of Atrium Medical Centre (Heerlen, The Netherlands), were
used for this study. The isolates were identiﬁed using the
VITEK 2 system (bioMe´rieux, Durham, NC, USA) [29] and
MICs were determined by Etests (AB Biodisk, Solna, Sweden).
E. coli, K. pneumoniae, Klebsiella oxytoca, P. aeruginosa, Acineto-
bacter baumannii and other Acinetobacter spp. with varying
degrees of insusceptibility to cefotaxime and ceftazidime were
tested. Seven known ESBL-producing isolates of E. coli, seven
known ESBL-producing isolates of K. pneumoniae and three
standard reference strains (E. coli ATCC 25922, P. aeruginosa
ATCC 27853 and K. pneumoniae ATCC 43816) were also
included in the study.
Antibiotics
Ceftazidime (Glaxo SmithKline, Zeist, The Netherlands) and
cefotaxime (Aventis Pharma, Hoevelaken, The Netherlands)
were used at eight concentrations: 0.1, 1, 5, 10, 20, 30, 40 and
50 mg ⁄L. Each experiment also contained a negative control
(no antibiotic) to serve as a reference for bacterial cell length.
Bacterial counts
The relationship between ﬁlament formation and CFUs was
determined in an experiment using E. coli ATCC 25922 grown
in broth in the presence of ceftazidime or cefotaxime at
concentrations of 0, 0.1, 1.0, 5.0, 10, 20, 30, 40 or 50 mg ⁄L. After
incubation for 4 h, samples were plated on blood agar using a
spiral plater (Whitley Automatic Spiral Plater; Don Whitley
Scientiﬁc, Shipley, UK). After overnight incubation, colonies
were counted, with a detection limit of 4 · 103 CFU ⁄mL. This
experiment was performed in triplicate.
Antibiotic exposure studies
One day before each experiment, two bacterial colonies were
suspended in tryptose phosphate broth and incubated over-
night to obtain cultures containing c. 108 CFU ⁄mL. Shortly
before the start of each experiment, a standard solution of
antibiotic was diluted in sterile saline to achieve the desired
concentrations, and 20 lL of each antibiotic dilution was
added to the wells of a microtitre plate. Subsequently, 180 lL
of bacterial suspension was added, mixed thoroughly, incu-
bated at 37C for 4 h, and then examined by light microscopy
following Gram’s stain.
Morphology
Following Gram’s stain, cultures were assessed by two
investigators using light microscopy at magniﬁcations of
·250, ·400 and ·1000. Filaments were classiﬁed as short (+)
if they had a length of three to ten bacterial cells, and as long
(++) if a length of ten or more bacterial cells was observed. The
two assessors were unaware of the identiﬁcation and MIC for
each isolate.
Statistical analysis
Statistical analysis was performed using SPSS v.10.0 for
Windows (SPSS Inc., Chicago, IL, USA) and GraphPad
Prism 3.0 (GraphPad Software Inc., San Diego, CA, USA).
Differences in ﬁlament-inducing concentrations were analysed
by multivariate analysis (ANOVA) for normally distributed
parameters, followed, when appropriate, by post-hoc t-tests.
Parameters without a normal distribution were analysed using
the non-parametric Kruskal–Wallis test, followed by the
Mann–Whitney test to investigate differences among groups.
Correlations among parameters with a normal distribution
were determined using Pearson’s correlation test. For non-
normally distributed parameters, Spearman’s rank correlation
test was applied. Statistical tests were considered signiﬁcant at
p <0.05.
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RESULTS
Viable counts
Fig. 1 shows the viable counts of E. coli ATCC
25922 following exposure to eight concentrations
of ceftazidime or cefotaxime for 4 h. At the start of
the experiments, the viable counts were
4 · 107 CFU ⁄mL, with untreated controls show-
ing an increase to 1 · 108 CFU ⁄mL after 4 h. All
antibiotic-treated cultures showed lower CFUs
after 4 h when compared to controls, including
cultures exposed to concentrations at or below the
MIC (0.19 mg ⁄L for ceftazidime, 0.064 mg ⁄L for
cefotaxime). Examination of Gram’s stains of the
cultures conﬁrmed the formation of ﬁlaments at
ceftazidime 0.1–10 mg ⁄L and cefotaxime 0.1–
1 mg ⁄L (Tables S1 and S2, see Supplementary
material).
Morphological studies
Morphological studies revealed that ﬁlaments
were shorter at the lowest and the highest
ﬁlament-inducing concentrations than in the
middle of the ﬁlament-inducing concentration
ranges (Fig. 2, Tables S1 and S2). In contrast to
E. coli, P. aeruginosa and Acinetobacter, all of
which showed long ﬁlaments at certain concen-
trations, isolates of Klebsiella showed short ﬁla-
ments only at the antibiotic concentrations
tested. Seven isolates, including six ESBL-pro-
ducing isolates with high MICs, did not form
ﬁlaments in this experiment. Also, one isolate of
K. pneumoniae (Kpn3; Tables S1 and S2) with
very low ceftazidime and cefotaxime MICs
(0.032 and 0.016 mg ⁄L, respectively) did not
show ﬁlamentous forms at any concentration
tested.
Exposure studies using ESBL-negative isolates
When bacterial families were compared, Entero-
bacteriaceae had signiﬁcantly lower maximum
ﬁlament-inducing concentrations of ceftazi-
dime, with a mean of 11.11 mg ⁄L (SD 7.7)
compared with 46.7 mg ⁄L (SD 8.2) for Pseudo-
monas spp. and 34.2 mg ⁄L (SD 22.7) for Acinet-
obacter spp. (p 0.0001 and 0.007, respectively).
For cefotaxime, the same pattern was found
(p 0.0001) (Tables S1 and S2).
Relative ﬁlament-inducing concentrations of
ceftazidime were higher for Enterobacteriaceae
(mean ratio 47.3 · MIC, SD 20.0) and Pseudomonas
spp. (mean ratio 55.3 · MIC, SD 39.0) than for
Acinetobacter spp. (mean 14.0 · MIC, SD 12.0)
(p 0.004 and 0.05, respectively). For cefotaxime,
the ratios were 36.9 · MIC (SD 50.0), 2.7 · MIC
(SD 2.0) and 5.1 · MIC (SD 4.6), respectively.
Again, the differences between Enterobacteria-
ceae and the other groups were signiﬁcant
(p 0.003 and 0.019, respectively). For cefotaxime,
there was also a signiﬁcant difference in the
lowest ﬁlament-inducing concentration for
Enterobacteriaceae (0.264 mg ⁄L, SD 0.369) and
either Pseudomonas spp. (9.2 mg ⁄L, SD 10.2) or
Acinetobacter spp. (3.2 mg ⁄L, SD 2.5) (p 0.009 and
0.001, respectively).
Comparing different Enterobacteraceae, similar
patterns were found for E. coli and Klebsiella spp.
for all values and both antibiotics. Within the
genus Klebsiella, there were differences among
isolates, with ﬁlaments being induced at higher
concentrations in K. oxytoca than in K. pneumoniae
(p 0.046 and p 0.018 for ceftazidime and cefotax-
ime, respectively).
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Fig. 1. Viable counts following incubation of Escherichia
coli ATCC 25922 for 4 h in the presence of varying
concentrations of ceftazidime or cefotaxime.
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Exposure studies using ESBL-positive isolates
Filament production was induced by ceftazidime
in eight of 14 ESBL-positive isolates, and by
cefotaxime in four ESBL-positive isolates. A clear
relationship between MIC and ﬁlament induction
was revealed in ESBL-positive isolates as, without
exception, the MICs for ﬁlament-producing ESBL-
positive isolates were £12 mg ⁄L.
When ESBL-positive and ESBL-negative iso-
lates of E. coli were compared, it was observed
that the lowest ﬁlament-inducing concentration of
ceftazidime increased from 2 mg ⁄L (SD 3.9) to
8 mg ⁄L (SD 9.0) (not signiﬁcant), and that the
highest ﬁlament-inducing concentration in-
creased from 8.3 (SD 6.1) to >50 mg ⁄L
(p 0.0001). Similarly, both values were also sig-
niﬁcantly higher for cefotaxime in ESBL-positive
isolates (p 0.006 and 0.0001 at the lowest and
highest concentrations, respectively).
Comparison of antibiotics
Ceftazidime induced the production of ﬁlaments
by 30 isolates, compared with 26 that were
induced using cefotaxime (Tables S1 and S2).
Overall, a trend toward larger ﬁlament-inducing
dose ranges was shown with ceftazidime (mean
29.9 mg ⁄L, SD 18.7) when compared to cefotax-
ime (mean 22.5 mg ⁄L, SD 18.9) (p 0.083). For
E. coli, the ﬁlament-inducing dose range was
signiﬁcantly wider following exposure to ceftaz-
idime (p 0.006). Overall, the MICs of ceftazidime
and cefotaxime were signiﬁcantly correlated
(r 0.882, p <0.0001), even when highly cefo-
taxime-insusceptible isolates of Pseudomonas were
included. The highest ﬁlament-inducing concen-
trations of ceftazidime and cefotaxime were sig-
niﬁcantly correlated (r 0.803, p 0.0001) when the
data for all isolates were combined.
DISCUSSION
The viable counts of E. coli were reduced follow-
ing exposure to ceftazidime or cefotaxime, even at
sub-MIC or MIC levels, compared to controls. At
low concentrations, this may reﬂect ﬁlament
formation rather than bacterial killing. This obser-
vation is explained by the fact that even large
ﬁlaments count as 1 CFU [2,3,30–32]. Most
E. coli
K. pneumoniae
P. aeruginosa
A. baumanniiFig. 2. Examples of morphological
experiments showing the appear-
ance (·100) of untreated cells (left),
short ﬁlaments and long ﬁlaments
(right) of Escherichia coli, Klebsiella
pneumoniae, Pseudomonas aeruginosa
and Acinetobacter baumannii.
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isolates produced large ﬁlaments (more than ten
cell lengths) at a certain dose range, but only short
ﬁlaments were encountered in Klebsiella spp., and
some isolates did not produce ﬁlamentous forms
at all. The absence of ﬁlament production by one
of the K. pneumoniae isolates (Kpn3) can be
explained by the very low MICs of both antibiot-
ics for this isolate, with ﬁlaments perhaps being
formed at concentrations <0.1 mg ⁄L, which were
not tested in the present study. In contrast, high
MICs serve as an explanation for all other isolates
that failed to produce ﬁlaments, as ﬁlament-
inducing concentrations were correlated signiﬁ-
cantly with MICs. It was concluded that the
relative degree of PBP-binding, which is reﬂected
by the change in morphology, probably differs for
each combination of antibiotic and bacterial family,
genus or isolate.
In support of this hypothesis, patterns among
families, genera or isolates were recognisable.
Within the Enterobacteriaceae, a pattern of short
dose ranges for ﬁlament production at low ceft-
azidime and cefotaxime concentrations was
observed, which was clearly related to the low
MICs for these isolates. For Pseudomonas and
Acinetobacter spp., ﬁlaments were induced by
b-lactams up to high concentrations. For most
combinations, ﬁlament induction starts at sub-
MIC or MIC levels, but may extend to concentra-
tions far above the MIC. Only for Acinetobacter
isolates was the highest ﬁlament-inducing con-
centration relatively low (14 · MIC). In ESBL-
positive isolates, ﬁlament induction may still be
present, but ﬁlament-inducing concentrations are
shifted towards higher levels compared with
those for non-ESBL producing isolates of the
same genus. Ceftazidime induced ﬁlament pro-
duction in more isolates than did cefotaxime, and
particularly in some ESBL-positive isolates.
Apparently, the ESBLs were more active against
cefotaxime, which was reﬂected by the relatively
higher MICs for these isolates. Some isolates,
especially Pseudomonas and Acinetobacter spp. and
ESBL-positive isolates, showed ﬁlament produc-
tion at the highest antibiotic concentrations tested,
which suggests the possibility of ﬁlament pro-
duction at even higher antibiotic concentrations.
The most important conclusion of this study is
that extensive production of ﬁlaments may occur
during exposure of relatively insusceptible micro-
organisms to clinically relevant concentrations of
antibiotics. Such ﬁlament induction may cause
exaggerated release of endotoxin, and should be
regarded as a negative phenomenon. In order to
prevent further augmentation of the already
existing risks of antibiotic resistance, empirical
antibiotic treatment in the early stages of serious
infections should probably include relatively high
concentrations or continuous dosing of antibiot-
ics.
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